
Barcoded human cells engineered with heterozygous genetic diversity to uncover toxicodynamic variabilityAward last edited on: 2/17/2024
Sponsored Program
SBIRAwarding Agency
NIH : NIEHSTotal Award Amount
$1,929,804Award Phase
2Solicitation Topic Code
113Principal Investigator
Jay GeorgeCompany Information
Amelia Technologies LLC
1121 5th Street NW
Washington, DC 20001
Washington, DC 20001
(202) 803-2614 |
info@ameliatechnologies.com |
www.ameliatechnologies.com |
Location: Single
Congr. District: 00
County: District of Columbia
Congr. District: 00
County: District of Columbia
Phase I
Contract Number: 1R44ES032522-01Start Date: 2/12/2021 Completed: 1/31/2022
Phase I year
2021Phase I Amount
$250,051Public Health Relevance Statement:
Project Narrative This Phase I/II fast track proposal will yield the development of a defined panel of barcoded, human cells with genetic diversity in genotoxin-response gene families: DNA damage response/repair, cell death and stress response. This system will provide a rapid and high-throughput, barcode-based analysis of toxicodynamic variability coupled with mechanistic insight that contributes to the variability in genotoxin response.
Project Terms:
Alleles; Allelomorphs; Bacteria; Bar Codes; barcode; Cell Cycle; Cell Division Cycle; Cell Death; necrocytosis; Cell Line; CellLine; Strains Cell Lines; cultured cell line; Cell Survival; Cell Viability; Cells; Cell Body; Diploidy; Diploid; DNA Damage; DNA Injury; Eligibility Determination; Eligibility; Protocol Screening; Exons; Flow Cytometry; Flow Cytofluorometries; Flow Cytofluorometry; Flow Microfluorimetry; Flow Microfluorometry; flow cytophotometry; Gene Expression; Genes; Goals; Grant; Heterozygote; heterozygosity; Human; Modern Man; Hypersensitivity; Allergy; In Vitro; Laboratories; Leadership; Mus; Mice; Mice Mammals; Murine; Mutagens; Genotoxins; genotoxic agent; Nucleotides; Genetic Polymorphism; polymorphism; Quality Control; Rattus; Common Rat Strains; Rat; Rats Mammals; Research Personnel; Investigators; Researchers; Testing; Toxicology; Genetic Variation; Genetic Diversity; Work; biological adaptation to stress; reaction; crisis; stress response; stress; reaction; Sequence Analysis; SEQ-AN; Sequence Analyses; base; repaired; repair; Phase; Variant; Variation; insight; Toxicity Tests; Toxicity Testing; Funding; Genetic; Exposure to; System; preference; Lytotoxicity; cytotoxicity; genotoxicity; knockout gene; Animal Models and Related Studies; model of animal; model organism; Animal Model; response; cell engineering; cellular engineering; Drops; Diploid Cells; Address; Cellular Stress; cell stress; Gene Family; Small Business Innovation Research Grant; SBIR; Small Business Innovation Research; Validation; Knock-out; Knockout; Development; developmental; novel strategies; new approaches; novel approaches; novel strategy; Outcome; Population; Coupled; Resistance; resistant; screening; Genomic DNA; gDNA; CRISPR/Cas technology; CRISPR method; CRISPR methodology; CRISPR technique; CRISPR technology; CRISPR-CAS-9; CRISPR-based method; CRISPR-based technique; CRISPR-based technology; CRISPR-based tool; CRISPR/Cas method; CRISPR/Cas9; CRISPR/Cas9 technology; Cas nuclease technology; Clustered Regularly Interspaced Short Palindromic Repeats method; Clustered Regularly Interspaced Short Palindromic Repeats methodology; Clustered Regularly Interspaced Short Palindromic Repeats technique; Clustered Regularly Interspaced Short Palindromic Repeats technology; inter-individual variation; inter-individual variability; interindividual variability; interindividual variation
Phase II
Contract Number: 4R44ES032522-02Start Date: 2/12/2021 Completed: 6/30/2024
Phase II year
2022(last award dollars: 2023)
Phase II Amount
$1,679,753Public Health Relevance Statement:
Project Narrative This Phase I/II fast track proposal will yield the development of a defined panel of barcoded, human cells with genetic diversity in genotoxin-response gene families: DNA damage response/repair, cell death and stress response. This system will provide a rapid and high-throughput, barcode-based analysis of toxicodynamic variability coupled with mechanistic insight that contributes to the variability in genotoxin response.
Project Terms:
Alleles; Allelomorphs; Bacteria; Bar Codes; barcode; Cell Cycle; Cell Division Cycle; Cell Death; necrocytosis; Cell Line; CellLine; Strains Cell Lines; cultured cell line; Cell Survival; Cell Viability; Cells; Cell Body; Diploidy; Diploid; DNA Damage; DNA Injury; Eligibility Determination; Eligibility; Protocol Screening; Exons; Flow Cytometry; Flow Cytofluorometries; Flow Cytofluorometry; Flow Microfluorimetry; Flow Microfluorometry; flow cytophotometry; Gene Expression; Genes; Goals; Grant; Heterozygote; heterozygosity; Human; Modern Man; Hypersensitivity; Allergy; In Vitro; Laboratories; Leadership; Mus; Mice; Mice Mammals; Murine; Mutagens; Genotoxins; genotoxic agent; Nucleotides; polymorphism; Genetic Polymorphism; Quality Control; Common Rat Strains; Rat; Rats Mammals; Rattus; Investigators; Researchers; Research Personnel; Testing; Toxicology; Genetic Variation; Genetic Diversity; Work; biological adaptation to stress; reaction; crisis; stress response; stress; reaction; Sequence Analysis; SEQ-AN; Sequence Analyses; base; repaired; repair; Phase; Variant; Variation; insight; Toxicity Testing; Toxicity Tests; Funding; Genetic; Exposure to; System; preference; Lytotoxicity; cytotoxicity; genotoxicity; knockout gene; Animal Models and Related Studies; model of animal; model organism; Animal Model; response; cell engineering; cellular engineering; Drops; Diploid Cells; Address; Cellular Stress; cell stress; Gene Family; Small Business Innovation Research Grant; SBIR; Small Business Innovation Research; Validation; Knock-out; Knockout; Development; developmental; novel strategies; new approaches; novel approaches; novel strategy; Outcome; Population; Coupled; Resistance; resistant; screening; Genomic DNA; gDNA; CRISPR/Cas technology; CRISPR approach; CRISPR based approach; CRISPR method; CRISPR methodology; CRISPR technique; CRISPR technology; CRISPR tools; CRISPR-CAS-9; CRISPR-based method; CRISPR-based technique; CRISPR-based technology; CRISPR-based tool; CRISPR/CAS approach; CRISPR/Cas method; CRISPR/Cas9; CRISPR/Cas9 technology; Cas nuclease technology; Clustered Regularly Interspaced Short Palindromic Repeats approach; Clustered Regularly Interspaced Short Palindromic Repeats method; Clustered Regularly Interspaced Short Palindromic Repeats methodology; Clustered Regularly Interspaced Short Palindromic Repeats technique; Clustered Regularly Interspaced Short Palindromic Repeats technology; inter-individual variation; inter-individual variability; interindividual variability; interindividual variation